Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Hero

Showing results (81-90 of 141) with videos related to

Pageof 15
Sort By:
Pediatric Blood & Cancer|April 7, 2021
Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplificationFrank Berthold, Carolina Rosswog, Holger Christiansen, et al.
Neoplasia (New York, N.Y.)|November 2, 2017
Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk AssessmentCarolina Rosswog, Rene Schmidt, André Oberthuer, et al.
Cancer Medicine|August 20, 2025
Anthracycline-Induced Cardiomyopathy After Nephro-/Neuroblastoma in Childhood: The Importance of Cardiological Reference AssessmentKristina Kleen, Judith Gebauer, Claudia Spix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratificationAndré Oberthuer, Frank Berthold, Patrick Warnat, et al.
Journal of Clinical Medicine|October 14, 2023
Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System RelapseTim Flaadt, Martin Ebinger, Malin Schreiber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Histone deacetylase 8 in neuroblastoma tumorigenesisIna Oehme, Hedwig E Deubzer, Dennis Wegener, et al.
Genome Biology|October 15, 2008
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomasFrank Westermann, Daniel Muth, Axel Benner, et al.
Cell & Bioscience|September 24, 2022
Reliable assessment of telomere maintenance mechanisms in neuroblastomaAlina Meeser, Christoph Bartenhagen, Lisa Werr, et al.
JMIR Research Protocols|February 17, 2022
Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort StudyOliver Zolk, Annika von dem Knesebeck, Norbert Graf, et al.
Journal of Cancer|July 30, 2016
Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALKChristine Damm-Welk, Faraz Siddiqi, Matthias Fischer, et al.
Pageof 15

Showing results (81-90 of 141) with videos related to

Sort By:
Pageof 15
Pediatric Blood & Cancer|April 7, 2021
Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplificationFrank Berthold, Carolina Rosswog, Holger Christiansen, et al.
Neoplasia (New York, N.Y.)|November 2, 2017
Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk AssessmentCarolina Rosswog, Rene Schmidt, André Oberthuer, et al.
Cancer Medicine|August 20, 2025
Anthracycline-Induced Cardiomyopathy After Nephro-/Neuroblastoma in Childhood: The Importance of Cardiological Reference AssessmentKristina Kleen, Judith Gebauer, Claudia Spix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratificationAndré Oberthuer, Frank Berthold, Patrick Warnat, et al.
Journal of Clinical Medicine|October 14, 2023
Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System RelapseTim Flaadt, Martin Ebinger, Malin Schreiber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Histone deacetylase 8 in neuroblastoma tumorigenesisIna Oehme, Hedwig E Deubzer, Dennis Wegener, et al.
Genome Biology|October 15, 2008
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomasFrank Westermann, Daniel Muth, Axel Benner, et al.
Cell & Bioscience|September 24, 2022
Reliable assessment of telomere maintenance mechanisms in neuroblastomaAlina Meeser, Christoph Bartenhagen, Lisa Werr, et al.
JMIR Research Protocols|February 17, 2022
Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort StudyOliver Zolk, Annika von dem Knesebeck, Norbert Graf, et al.
Journal of Cancer|July 30, 2016
Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALKChristine Damm-Welk, Faraz Siddiqi, Matthias Fischer, et al.
Pageof 15